Tag: clinical trials

Designing Escalation Paths for Site, Data and Vendor Issues

Posted on By digi

Designing Escalation Paths for Site, Data and Vendor Issues Designing Escalation Paths for Site, Data and Vendor Issues In the highly regulated field of clinical trials, effective issue management is paramount. Within clinical research organization companies, the process of identifying, escalating, and resolving issues is critical to ensuring trial integrity and compliance. This comprehensive guide…

Read More “Designing Escalation Paths for Site, Data and Vendor Issues” »

Issue Management & Escalation Paths

Integrated Issue Management Across CTMS, eTMF and Quality Systems

Posted on By digi

Integrated Issue Management Across CTMS, eTMF and Quality Systems Integrated Issue Management Across CTMS, eTMF and Quality Systems Integrated issue management is critical for the success of clinical trials, particularly in the evolving landscape of biosimilar clinical trials, til therapy clinical trials, and others like the donanemab clinical trial or Sanofi clinical trials. This tutorial…

Read More “Integrated Issue Management Across CTMS, eTMF and Quality Systems” »

Issue Management & Escalation Paths

Designing Systems and Processes That Embed ALCOA++ Principles

Posted on By digi

Designing Systems and Processes That Embed ALCOA++ Principles In an era where data integrity is paramount in clinical research, the principles of ALCOA++ are essential in ensuring the quality and reliability of clinical trial data. This step-by-step guide will provide clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU with…

Read More “Designing Systems and Processes That Embed ALCOA++ Principles” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Part 11 Requirements for Electronic Records, Signatures and Audit Trails

Posted on By digi

Part 11 Requirements for Electronic Records, Signatures and Audit Trails Understanding Part 11 Requirements for Electronic Records, Signatures and Audit Trails The advent of electronic records in clinical trials has revolutionized data management. However, it also introduces regulatory challenges that professionals must navigate to ensure compliance with international standards. This guide will provide a comprehensive…

Read More “Part 11 Requirements for Electronic Records, Signatures and Audit Trails” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Documenting Interim Analysis Plans in Protocol, SAP and Charter

Posted on By digi

Documenting Interim Analysis Plans in Protocol, SAP and Charter In the dynamically evolving landscape of clinical research, the necessity of interim analyses has become increasingly acknowledged by regulatory bodies and sponsors alike. Conducting interim analyses allows for the monitoring of data throughout the lifecycle of a clinical trial, potentially informing decisions regarding safety, efficacy, and…

Read More “Documenting Interim Analysis Plans in Protocol, SAP and Charter” »

Interim Analyses & Alpha Spending

Building Surveillance Capability in Lean Clinical Development Teams

Posted on By digi

Building Surveillance Capability in Lean Clinical Development Teams In the context of modern clinical trials, particularly those governed by ICH-GCP, FDA, EMA, and MHRA regulations, the need for robust surveillance capabilities has never been more critical. In this guide, we will delve into how to build surveillance capability within lean clinical development teams, focusing on…

Read More “Building Surveillance Capability in Lean Clinical Development Teams” »

Statistical Data Surveillance

Issue Management in RBM: From Signal to Actionable Resolution

Posted on By digi

Issue Management in RBM: From Signal to Actionable Resolution Risk-Based Monitoring (RBM) in clinical trials offers considerable advantages in ensuring the safety and efficacy of treatments while optimizing resource use. Effective issue management is crucial within this framework, necessitating a structured approach that allows clinical operations, regulatory affairs, and medical affairs professionals to identify, evaluate,…

Read More “Issue Management in RBM: From Signal to Actionable Resolution” »

Issue Management & Escalation Paths

Metrics for Standards Adoption, Rework and Submission Findings

Posted on By digi

Metrics for Standards Adoption, Rework and Submission Findings Metrics for Standards Adoption, Rework and Submission Findings In the realm of clinical trials, data management is a critical component that directly impacts the efficiency and accuracy of study results. The adoption of standardized data formats, particularly those established by the Clinical Data Interchange Standards Consortium (CDISC),…

Read More “Metrics for Standards Adoption, Rework and Submission Findings” »

Data Standards (CDISC: SDTM, ADaM)

Data Integrity in Clinical Trials: Applying ALCOA++ and 21 CFR Part 11

Posted on By digi

Data Integrity in Clinical Trials: Applying ALCOA++ and 21 CFR Part 11 Data integrity is paramount in clinical trials, underpinning the reliability of results and the safety of patients. This article will provide a comprehensive step-by-step guide for clinical research professionals to understand and implement the principles of ALCOA++ and the regulatory requirements of 21…

Read More “Data Integrity in Clinical Trials: Applying ALCOA++ and 21 CFR Part 11” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Adaptive Enrichment and Sample Size Re-Estimation at Interim

Posted on By digi

Adaptive Enrichment and Sample Size Re-Estimation at Interim Adaptive Enrichment and Sample Size Re-Estimation at Interim The ever-evolving landscape of clinical trials necessitates a robust and flexible approach to data analysis. This is particularly true in the context of interim analyses, where decisions must be made based on incomplete data. This step-by-step guide focuses on…

Read More “Adaptive Enrichment and Sample Size Re-Estimation at Interim” »

Interim Analyses & Alpha Spending